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The prognostic value of fixed time and self‑paced walking tests 
in patients diagnosed with idiopathic pulmonary fibrosis
Abstract
Idiopathic pulmonary fibrosis (IPF) is a specific form of chronic fibrosing interstitial pneumonia that has an unknown etiology. The 
natural history of the disease is characterized by a progressive decline in pulmonary function and overall health and well-being. 
The median survival time is between 2–3 years; however, the disease course is variable and unpredictable.
The twelve-minute walking test (12MWT) and six-minute walking test (6MWT) are two fixed time tests that are commonly used 
in clinical practice. Our short and clinically oriented narrative review attempted to summarize current evidence supporting the use 
of fixed time, self-paced walking tests in predicting the outcome of patients diagnosed with IPF. 
A number of studies have justified that the 6MWT is a simple, cost-effective, well documented, fixed time, and self-paced walking 
test which is a valid and reliable measure of disease status and can also be used as a prognostic tool in patients with IPF. However, 
there is a need for dedicated and validated reference equations for this population of patients. 
It is also necessary to fill the knowledge gap about the role of the 12MWT. We hypothesize that it would be useful in evaluating 
patients that are in the early stages of the disease. 
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Introduction
Idiopathic pulmonary fibrosis (IPF) is a spe-
cific form of chronic fibrosing interstitial pneu-
monia with an unknown etiology representing 
one of the most common entities of the heteroge-
neous group of interstitial lung diseases (ILDs). 
The prevalence of this rare disease is estimated 
to be at 2–29 cases per 100,000 in the general 
population [1–5]. The natural history of the dis-
ease is characterized by a progressive decline in 
pulmonary function as well as overall health and 
well-being. The median survival time is between 
2–3 years but the disease course is variable and 
unpredictable [6–9].
The most common symptoms of this pro-
gressive disease include exertional dyspnea and 
dry cough. The symptoms usually appear insid-
iously and many patients are unable to pinpoint 
the date of their appearance. It is important to 
note that deteriorating exercise tolerance often 
fails to alarm patients about the early stages 
of IPF because these patients tend to attribute 
their symptoms to the ageing process or treat 
them as a consequence of long-term tobacco 
smoking [10].
Progression dynamics clearly have an effect 
on the prognosis in IPF. Objective measurement 
of exercise capacity is one of the ways to monitor 
the disease course [11].
Cardiopulmonary exercise testing (CPET) is 
an objective assessment of exercise capacity and, 
in recent times, has become a more commonly 
used tool in clinical settings. However, CPET 
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involves the use of specialized facilities that are 
not universally available. That is why simple 
fixed time and self-paced walking tests are more 
frequently used in the clinical assessment of ex-
ercise capacity. The twelve-minute walking test 
(12MWT) and six-minute walking test (6MWT) 
are two fixed time tests commonly used in clin-
ical practice.
Our short and clinically oriented narrative 
review attempted to summarize current evidence 
supporting the use of fixed time and self-paced 
walking tests in predicting the outcome for pa-
tients diagnosed with IPF. 
Selected aspects of exercise pathophysiology 
in fibrotic interstitial lung diseases
The background of exercise intolerance in 
IPF patients is a complex, multidimensional, and 
multi-faceted issue. Most of the previous studies 
on exercise intolerance in patients with ILDs were 
performed on broad ILD populations which also 
included patients suffering from other fibrotic 
interstitial lung diseases, not only IPF. That be-
ing said, we may assume that these entities are 
comparable because the disease mechanisms 
involve a fibrotic process. From a pathophysi-
ological point of view, fibrotic changes in the 
lungs lead to decreased lung compliance, which 
in turn results in an increased work of breathing 
and decreased lung volumes. These abnormalities 
present clinically as a classic restrictive pattern 
of lung disease. Patients develop a decreased total 
lung capacity, vital capacity, and inspirational 
capacity. These, in turn, result in a decreased 
tidal volume and an increased respiratory rate 
which leads to increased ventilation and, even-
tually, hypocapnia. Alveolar-capillary membrane 
thickening causes decreased oxygen diffusion 
and a ventilation-perfusion mismatch. In order 
to compensate for the resulting hypoxemia, the 
body increases ventilation. Clinically, hypoxemia 
is associated with a sensation of dyspnea. It also 
results in the constriction of pulmonary vessels 
and a subsequent decrease in cardiac output 
which leads to decreased delivery of oxygen to 
the muscles and resulting fatigue. IPF patients 
commonly present with weakness of the mus-
culature of the lower limbs which contributes to 
exercise intolerance. It is important to mention 
that pulmonary microvasculopathy also contrib-
utes to decreased cardiac output. These vascular 
changes are a result of endothelial proliferation, 
remodeling, and capillary obliteration. Decreased 
oxygen delivery to the muscles will also result in 
increased oxygen extraction and, subsequently, 
decreased venous oxygen capacity which poten-
tiates hypoxemia [12–29].
In summary, the complex aforementioned 
mechanisms lead to primary symptoms of dys-
pnea and fatigue which, together, form the basis 
of exercise intolerance. 
General principles of the 12MWT and the 6MWT
The 12MWT is based on a 12-minute per-
formance test introduced by Cooper et al. as 
a guide to determine the state of physical fitness 
in healthy young men [30]. The authors observed 
that field testing can provide a good assessment 
of maximal oxygen consumption in young and 
well-motivated subjects. However, the accuracy of 
the estimate is related directly to the motivation of 
the subjects [30]. The test requires the patient to 
cover the maximum possible distance in 12 min-
utes by running, walking, or using a combination 
of both [31]. Results of the 12MWT are highly 
reproducible [32]. The prediction of cardiore-
spiratory fitness in this test is described by the 
following equation [31]: VO2max (mL/kg/min) = 
(distance [m] – 504.9)/44.73.
The 6MWT is considered a simple, cost-ef-
fective, and well-documented field test for the 
assessment of the functional exercise capacity. 
It can also be used to assess the response to 
medical interventions in various diseases. It was 
introduced as a therapeutic tool in respiratory 
medicine by Butland et al. [33] in their study com-
paring three fixed time tests (2-, 6-, and 12-minute 
walking tests) and they concluded that shorter 
distance tests would be just as beneficial as the 
12MWT.  The authors also observed high correla-
tion coefficients between the 2-, 6-, and 12-minute 
tests. This indicates that they were similar mea-
sures of exercise tolerance. All of these tests 
showed equal reproducibility. However, the 
longer tests presented a greater discrimination 
than the shorter ones [33]. Therefore, the 6MWT 
seems to be a satisfactory compromise between 
test validity and patient acceptability. Nowadays, 
this is the most common fixed distance test used 
in clinical and research settings.
Mänttäri et al. observed that the 6MWT per-
formed on a 15 m track may predict a VO2 max in 
healthy adults with an accuracy of about 1 meta-
bolic equivalent (MET). The following equations 
were proposed [34]:
— For men:
VO2max (mL/kg/min) = 110.546 + 0.063 × 
distance – 0.250 × age – 0.486 × BMI – 0.42 × 
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height [cm] – 0.109 × heart rate at the end 
of the test,
— For women:
VO2max (mL/kg/min) = 22.506 – 0.271 × 
weight + 0.051 × distance – 0.065 × age.
The prognostic value of the 12MWT 
and the 6MWT in IPF
The 12MWT is less commonly used for IPF 
patients because it requires greater effort by the 
patient than the 6MWT. We hypothesize that it 
would be useful in evaluating patients in the early 
stages of the disease. However, it is important to 
mention that our research is currently in progress 
and that this is only a running hypothesis. 
On the other hand, there is a growing body 
of evidence supporting the role of the 6MWT in 
the evaluation of IPF patients. Caminati et al. [35] 
performed a retrospective analysis of 44 patients 
with IPF of whom 29 had an additional evalua-
tion at follow-up after 12 months. During a mean 
follow-up period of 19.8 months, 11 patients died 
because of IPF. The authors observed that the 
distance walked in 6 minutes (6MWD) was inde-
pendently related to mortality and that patients 
who walked less than 212 meters had a signifi-
cantly lower survival rate than those who were 
able to walk a longer distance. Changes in dis-
tance walked upon evaluation at 12 months were 
also predictive of survival. Du Bois et al. aimed to 
assess the reliability, validity, and responsiveness 
of the 6MWD. At the conclusion of their study, 
they estimated the minimal clinically important 
difference in IPF patients as 24–45 m [36]. The 
6MWD was measured at baseline and at 24-week 
intervals. A comparison of two proximal measures 
of the 6MWD demonstrated good reliability. As 
was previously cited in the Caminati et al. study, 
these authors also observed that a change in the 
results of the 6MWD was highly predictive of 
mortality. Moreover, test results weakly correlat-
ed with forced vital capacity, diffusion capacity 
of the lung for carbon monoxide, resting alveo-
lar–arterial gradient, and health-related quality 
of life. Measured values were consistently and 
significantly lower for patients with the poorest 
functional status. For example, a patient who, at 
baseline, covered a distance of less than 250 m 
was associated with a 2.65-fold increased risk of 
death over the following year when compared 
with a patient who was able to cover a distance 
of more than 350m. On the flip side, a decline in 
distance covered of 50 meters or more was associ-
ated with a 4.27-fold increased risk of death over 
the following year when compared with patients 
whose deterioration was capped at a maximum 
of 25 meters [36]. Three years later, the authors 
published another paper in which they proved 
that both the 6MWD and resulting changes in 
6MWD results were independent predictors of 
mortality in patients with IPF [37].
Moreover, in a study of 197 patients con-
ducted by Flaherty et al., the authors observed 
that desaturation during the 6MWT was asso-
ciated with an increased mortality rate even 
though a threshold of 88% was not reached. 
Moreover, for patients with a baseline satu-
ration of 88% or less, the strongest observed 
predictor of mortality was a serial change in 
the lung transfer factor for carbon monoxide. 
However, for patients who had a saturation 
over 88% during their baseline walking test, 
serial decreases in forced vital capacity (FVC) 
and increases in desaturation area significantly 
predicted subsequent mortality [38].
Another interesting and clinically important 
study was performed by Lederer et al. who an-
alyzed the association between the 6MWD and 
survival in 454 patients with IPF who were listed 
for lung transplantation. This study showed that 
a shorter 6MWD result was associated with an 
increased mortality rate. Moreover, patients who 
covered a distance of less than 207m had a four-
fold greater mortality rate even after adjusting for 
demographics, anthropomorphic measurements, 
FVC expressed as percent of predicted, pulmonary 
hypertension, and medical comorbidities. They 
stated that the 6MWD was a significantly better 
predictor of six-month mortality than FVC ex-
pressed as a percent of predicted value [39]. 
Kozu et al. [40], in their prospective, 
cross-sectional observational study, assessed the 
relationship between the Medical Research Coun-
cil (MRC) dyspnea grade and peripheral muscle 
force, activities of daily living performance, 
health status, lung function, and exercise capac-
ity in 65 IPF patients in a stable clinical state. 
The authors noted a strong association between 
MRC grade and the 6MWD. Similarly, Manali et 
al. [41] prospectively studied the relationship 
between the MRC chronic Dyspnea Scale with 
cardiopulmonary exercise testing (CPET) and the 
6MWT in 25 IPF patients. They found significant 
correlations between the MRC score and the fol-
lowing parameters of the 6MWT: distance walked, 
SpO2 at initiation and at the end of the test, and 
the difference in saturation before and after the 
test. Correlations with the pulse at the initiation 
and at the end of the test, the blood pressure, 
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and the Borg dyspnea scale were not significant. 
A multiple stepwise logistic regression analysis 
that tested a number of physiologic parameters 
showed that the only variable independently re-
lated to the MRC score was the distance walked 
at the 6MWT.
Confounding factors
A considerable number of factors, both in-
ternal and external, can affect the result of the 
6MWT. That is why a low 6MWD may be non-spe-
cific and non-diagnostic. In the event of a low 
6MWT test result, it is important to further 
research whether or not such a result is reliable 
and accurate. Moreover, it would be helpful 
to analyze the 6MWT results in the context of 
pulmonary function tests, cardiac function, nu-
tritional status, muscle strength, ankle–brachial 
index, orthopedic function, and cognitive func-
tion. From a constitutional point of view, age, 
height, weight, and sex independently affect the 
6MWD in healthy adults [42]. It is important to 
note that a shorter walking corridor, decreased 
patient motivation, comorbidities, medications, 
oxygen supplementation, and previous experi-
ence with the test can affect the result [43]. This 
information highlights the need for specific ref-
erence equations. 
Reference equations
There are some reference equations for the 
6MWT published in literature [44–52] which are 
not validated for the IPF population. However, in 
this context, it is worth to discuss a prospective, 
non-randomized controlled study conducted by 
Igarashi et al. In this study, the authors inves-
tigated the effect of an outpatient pulmonary 
rehabilitation program and the use of 6MWD (ex-
pressed as a percentage of the predicted value) to 
quantify the response to pulmonary rehabilitation 
in elderly patients with ILDs. They concluded that 
6MWD, expressed as a percentage of the predicted 
value, might be more useful than the absolute 
6MWD as an outcome measure of pulmonary 
rehabilitation, and as a predictor of response to 
pulmonary rehabilitation in elderly patients with 
ILDs [53]. The authors used reference equations 
proposed by Enright et al. [52].
Therefore, the body of evidence regarding the 
reference equations for the 6MWT in IPF shows 
that there are considerable gaps of knowledge in 
this area and highlights the need for comprehen-
sive exploration of this topic. 
Conclusions
The 6MWT is a simple, cost-effective, 
well-documented, fixed time, and self-paced 
walking test evaluating functional capacity which 
is broadly used for clinical and research purpos-
es. The 6MWT result is a valid and reliable mea-
sure of disease status and prognosis in patients 
with IPF. Nevertheless, there is a need to establish 
dedicated and validated reference equations for 
this population of patients. 
There is also a need to fill the knowledge gap 
regarding the role of the 12MWT in this population. 
We hypothesize that it would be useful in evaluat-




1. Karakatsani A, Papakosta D, Rapti A, et al. Epidemiology of 
interstitial lung diseases in Greece. Respir Med. 2009; 103(8): 
1122–1129, doi: 10.1016/j.rmed.2009.03.001, indexed in 
Pubmed: 19345567.
2. von Plessen C, Grinde O, Gulsvik A. Incidence and prev-
alence of cryptogenic fibrosing alveolitis in a Norwegian 
community. Respir Med. 2003; 97(4): 428–435, doi: 10.1053/
rmed.2002.1466, indexed in Pubmed: 12693805.
3. Coultas DB, Zumwalt RE, Black WC, et al. The epidemiology 
of interstitial lung diseases. Am J Respir Crit Care Med. 1994; 
150(4): 967–972, doi: 10.1164/ajrccm.150.4.7921471, indexed 
in Pubmed: 7921471.
4. Iwai K, Mori T, Yamada N, et al. Idiopathic pulmonary fibro-
sis. Epidemiologic approaches to occupational exposure. Am 
J Respir Crit Care Med. 1994; 150(3): 670–675, doi: 10.1164/
ajrccm.150.3.8087336, indexed in Pubmed: 8087336.
5. Scott J, Johnston I, Britton J. What causes cryptogenic fibros-
ing alveolitis? A case-control study of environmental expo-
sure to dust. BMJ. 1990; 301(6759): 1015–1017, doi: 10.1136/
bmj.301.6759.1015, indexed in Pubmed: 2249047.
6. Raghu G, Remy-Jardin M, Myers JL, et al. An official ATS/
ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: ev-
idence-based guidelines for diagnosis and management. Am 
J Respir Crit Care Med. 2011; 183(6): 788–824, doi: 10.1164/
rccm.2009-040GL, indexed in Pubmed: 21471066.
7. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/
JRS/ALAT statement: idiopathic pulmonary fibrosis: evi-
dence-based guidelines for diagnosis and management. Am 
J Respir Crit Care Med. 2011; 183(6): 788–824, doi: 10.1164/
rccm.2009-040GL, indexed in Pubmed: 21471066.
8. Ley B, Collard HR, King TE. Clinical course and predic-
tion of survival in idiopathic pulmonary fibrosis. Am J Re-
spir Crit Care Med. 2011; 183(4): 431–440, doi: 10.1164/rc-
cm.201006-0894CI, indexed in Pubmed: 20935110.
9. Rudd RM, Prescott RJ, Chalmers JC, et al. British Thoracic 
Society Study on cryptogenic fibrosing alveolitis: Response 
to treatment and survival. Thorax. 2007; 62(1): 62–66, doi: 
10.1136/thx.2005.045591, indexed in Pubmed: 16769717.
10. Piotrowski WJ, Bestry I, Białas AJ, et al. Guidelines of the 
Polish Respiratory Society for diagnosis and treatment of id-
iopathic pulmonary fibrosis. Adv Respir Med. 2020; 88(1): 
41–93, doi: 10.5603/ARM.2020.0081, indexed in Pubmed: 
32153010.
11. Ley B, Bradford WZ, Vittinghoff E, et al. Predictors of mortality 
poorly predict common measures of disease progression in id-
iopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2016; 
Adam J Białas et al., Fixed time, self-paced walking tests in IPF
53www.journals.viamedica.pl
194(6): 711–718, doi: 10.1164/rccm.201508-1546OC, indexed 
in Pubmed: 26938706.
12. Du Plessis JP, Fernandes S, Jamal R, et al. Exertional hypox-
emia is more severe in fibrotic interstitial lung disease than 
in COPD. Respirology. 2018; 23(4): 392–398, doi: 10.1111/
resp.13226, indexed in Pubmed: 29193512.
13. Schaeffer MR, Ryerson CJ, Ramsook AH, et al. Neurophys-
iological mechanisms of exertional dyspnoea in fibrot-
ic interstitial lung disease. Eur Respir J. 2018; 51(1), doi: 
10.1183/13993003.01726-2017, indexed in Pubmed: 29348183.
14. Murray LA, Habiel DM, Hohmann M, et al. Antifibrotic role of 
vascular endothelial growth factor in pulmonary fibrosis. JCI 
Insight. 2017; 2(16), doi: 10.1172/jci.insight.92192, indexed in 
Pubmed: 28814671.
15. Troy LK, Young IH, Lau EMT, et al. Exercise pathophysiol-
ogy and the role of oxygen therapy in idiopathic interstitial 
pneumonia. Respirology. 2016; 21(6): 1005–1014, doi: 10.1111/
resp.12650, indexed in Pubmed: 26416262.
16. Vainshelboim B, Kramer MR, Fox BD, et al. Exercise training-based 
pulmonary rehabilitation program is clinically beneficial for idio-
pathic pulmonary fibrosis. Respiration. 2014; 88(5): 378–388, doi: 
10.1159/000367899, indexed in Pubmed: 25341682.
17. Faisal A, Alghamdi BJ, Ciavaglia CE, et al. Common mechanisms 
of dyspnea in chronic interstitial and obstructive lung disorders. 
Am J Respir Crit Care Med. 2016; 193(3): 299–309, doi: 10.1164/
rccm.201504-0841OC, indexed in Pubmed: 26407036.
18. Degani-Costa LH, Levarge B, Digumarthy SR, et al. Pulmo-
nary vascular response patterns during exercise in intersti-
tial lung disease. Eur Respir J. 2015; 46(3): 738–749, doi: 
10.1183/09031936.00191014, indexed in Pubmed: 25976688.
19. Nolan CM, Kon SSC, Canavan JL, et al. Preferential lower limb 
muscle weakness in idiopathic pulmonary fibrosis: Effects on 
exercise capacity. . Eur Respir J. 2014; 44(58). Available online: 
https://erj.ersjournals.com/content/44/Suppl_58/P4492. [Last 
accessed: 24.04.2020].
20. O’Donnell DE, Ora J, Webb KA, et al. Mechanisms of activi-
ty-related dyspnea in pulmonary diseases. Respir Physiol Neu-
robiol. 2009; 167(1): 116–132, doi: 10.1016/j.resp.2009.01.010, 
indexed in Pubmed: 19450767.
21. O’Donnell DE, Hong HH, Webb KA. Respiratory sensation 
during chest wall restriction and dead space loading in exer-
cising men. J Appl Physiol (1985). 2000; 88(5): 1859–1869, doi: 
10.1152/jappl.2000.88.5.1859, indexed in Pubmed: 10797151.
22. Nava S, Rubini F. Lung and chest wall mechanics in ventilated 
patients with end stage idiopathic pulmonary fibrosis. Thorax. 
1999; 54(5): 390–395, doi: 10.1136/thx.54.5.390, indexed in 
Pubmed: 10212101.
23. O’Donnell DE, Chau LK, Webb KA. Qualitative aspects of ex-
ertional dyspnea in patients with interstitial lung disease. J 
Appl Physiol (1985). 1998; 84(6): 2000–2009, doi: 10.1152/
jappl.1998.84.6.2000, indexed in Pubmed: 9609795.
24. Markovitz GH, Cooper CB. Exercise and interstitial lung disease. 
Curr Opin Pulm Med. 1998; 4(5): 272–280, doi: 10.1097/00063198-
199809000-00006, indexed in Pubmed: 10813202.
25. Hansen JE, Wasserman K. Pathophysiology of activity lim-
itation in patients with interstitial lung disease. Chest. 1996; 
109(6): 1566–1576, doi: 10.1378/chest.109.6.1566, indexed in 
Pubmed: 8769513.
26. Marciniuk DD, Sridhar G, Clemens RE, et al. Lung volumes 
and expiratory flow limitation during exercise in interstitial 
lung disease. J Appl Physiol (1985). 1994; 77(2): 963–973, doi: 
10.1152/jappl.1994.77.2.963, indexed in Pubmed: 8002554.
27. Javaheri S, Sicilian L. Lung function, breathing pattern, and 
gas exchange in interstitial lung disease. Thorax. 1992; 47(2): 
93–97, doi: 10.1136/thx.47.2.93, indexed in Pubmed: 1549829.
28. Agustí AG, Roca J, Gea J, et al. Mechanisms of gas-exchange 
impairment in idiopathic pulmonary fibrosis. Am Rev Respir 
Dis. 1991; 143(2): 219–225, doi: 10.1164/ajrccm/143.2.219, in-
dexed in Pubmed: 1990931.
29. Risk C, Epler GR, Gaensler EA. Exercise alveolar-arterial ox-
ygen pressure difference in interstitial lung disease. Chest. 
1984; 85(1): 69–74, doi: 10.1378/chest.85.1.69, indexed in 
Pubmed: 6690254.
30. Cooper KH. A means of assessing maximal oxygen intake. 
Correlation between field and treadmill testing. JAMA. 1968; 
203(3): 201–204, indexed in Pubmed: 5694044.
31. Liguori G (ed.). ACSM’s Health-Related Physical Fitness As-
sessment Manual. 5th edition. 2018.
32. Mungall IP, Hainsworth R. Assessment of respiratory function 
in patients with chronic obstructive airways disease. Thorax. 
1979; 34(2): 254–258, doi: 10.1136/thx.34.2.254, indexed in 
Pubmed: 483195.
33. Butland RJ, Pang J, Gross ER, et al. Two-, six-, and 12-minute 
walking tests in respiratory disease. Br Med J (Clin Res Ed). 
1982; 284(6329): 1607–1608, doi: 10.1136/bmj.284.6329.1607, 
indexed in Pubmed: 6805625.
34. Mänttäri A, Suni J, Sievänen H, et al. Six-minute walk test: a 
tool for predicting maximal aerobic power (VO max) in healthy 
adults. Clin Physiol Funct Imaging. 2018 [Epub ahead of print], 
doi: 10.1111/cpf.12525, indexed in Pubmed: 29851229.
35. Caminati A, Bianchi A, Cassandro R, et al. Walking distance 
on 6-MWT is a prognostic factor in idiopathic pulmonary 
fibrosis. Respir Med. 2009; 103(1): 117–123, doi: 10.1016/j.
rmed.2008.07.022, indexed in Pubmed: 18786822.
36. du Bois RM, Weycker D, Albera C, et al. Six-minute-walk test 
in idiopathic pulmonary fibrosis: test validation and minimal 
clinically important difference. Am J Respir Crit Care Med. 
2011; 183(9): 1231–1237, doi: 10.1164/rccm.201007-1179OC, 
indexed in Pubmed: 21131468.
37. du Bois RM, Albera C, Bradford WZ, et al. 6-Minute walk distance 
is an independent predictor of mortality in patients with idio-
pathic pulmonary fibrosis. Eur Respir J. 2014; 43(5): 1421–1429, 
doi: 10.1183/09031936.00131813, indexed in Pubmed: 24311766.
38. Flaherty KR, Andrei AC, Murray S, et al. Idiopathic pul-
monary fibrosis: prognostic value of changes in physiology 
and six-minute-walk test. Am J Respir Crit Care Med. 2006; 
174(7): 803–809, doi: 10.1164/rccm.200604-488OC, indexed 
in Pubmed: 16825656.
39. Lederer DJ, Arcasoy SM, Wilt JS, et al. Six-minute-walk dis-
tance predicts waiting list survival in idiopathic pulmonary 
fibrosis. Am J Respir Crit Care Med. 2006; 174(6): 659–664, doi: 
10.1164/rccm.200604-520OC, indexed in Pubmed: 16778159.
40. Kozu R, Jenkins S, Senjyu H. Evaluation of activity limita-
tion in patients with idiopathic pulmonary fibrosis grouped 
according to Medical Research Council dyspnea grade. Arch 
Phys Med Rehabil. 2014; 95(5): 950–955, doi: 10.1016/j.
apmr.2014.01.016, indexed in Pubmed: 24502840.
41. Manali ED, Lyberopoulos P, Triantafillidou C, et al. MRC 
chronic Dyspnea Scale: Relationships with cardiopulmo-
nary exercise testing and 6-minute walk test in idiopathic 
pulmonary fibrosis patients: a prospective study. BMC Pulm 
Med. 2010; 10: 32, doi: 10.1186/1471-2466-10-32, indexed in 
Pubmed: 20509928.
42. ATS Committee on Proficiency Standards for Clinical Pul-
monary Function Laboratories. ATS statement: guidelines for 
the six-minute walk test. Am J Respir Crit Care Med. 2002; 
166(1): 111–117, doi: 10.1164/ajrccm.166.1.at1102, indexed in 
Pubmed: 12091180.
43. Enright PL. The six-minute walk test. Respir Care. 2003 
Aug;48(8): 783–785.
44. Palaniappan Ramanathan R, Chandrasekaran B. Reference 
equations for 6-min walk test in healthy Indian subjects (25-
80 years). Lung India. 2014; 31(1): 35–38, doi: 10.4103/0970-
2113.125892, indexed in Pubmed: 24669079.
45. Vaish H, Ahmed F, Singla R, et al. Reference equation for 
the 6-minute walk test in healthy North Indian adult males. 
Int J Tuberc Lung Dis. 2013; 17(5): 698–703, doi: 10.5588/
ijtld.12.0474, indexed in Pubmed: 23575339.
46. Casanova C, Celli BR, Barria P, et al. The 6-min walk dis-
tance in healthy subjects: reference standards from sev-
en countries. Eur Respir J. 2011; 37(1): 150–156, doi: 
10.1183/09031936.00194909, indexed in Pubmed: 20525717.
47. Hill K, Wickerson LM, Woon LJ, et al. The 6-min walk test: 
responses in healthy Canadians aged 45 to 85 years. Appl 
Physiol Nutr Metab. 2011; 36(5): 643–649, doi: 10.1139/h11-
075, indexed in Pubmed: 21967531.
48. Cote CG, Casanova C, Marín JM, et al. Validation and comparison 
of reference equations for the 6-min walk distance test. Eur Re-
spir J. 2008; 31(3): 571–578, doi: 10.1183/09031936.00104507, 
indexed in Pubmed: 17989117.
Advances in Respiratory Medicine 2021, vol. 89, no. 1, pages 49–54
54 www.journals.viamedica.pl
49. Chetta A, Zanini A, Pisi G, et al. Reference values for the 6-min 
walk test in healthy subjects 20-50 years old. Respir Med. 
2006; 100(9): 1573–1578, doi: 10.1016/j.rmed.2006.01.001, in-
dexed in Pubmed: 16466676.
50. Gibbons WJ, Fruchter N, Sloan S, et al. Reference values for 
a multiple repetition 6-minute walk test in healthy adults 
older than 20 years. J Cardiopulm Rehabil. 2001; 21(2): 87–93, 
doi: 10.1097/00008483-200103000-00005, indexed in Pubmed: 
11314289.
51. Troosters T, Gosselink R, Decramer M. Six minute walking 
distance in healthy elderly subjects. Eur Respir J. 1999; 14(2): 
270–274, doi: 10.1034/j.1399-3003.1999.14b06.x, indexed in 
Pubmed: 10515400.
52. Enright PL, Sherrill DL. Reference equations for the six-minute 
walk in healthy adults. Am J Respir Crit Care Med. 1998; 158(5 
Pt 1): 1384–1387, doi: 10.1164/ajrccm.158.5.9710086, indexed 
in Pubmed: 9817683.
53. Igarashi Ai, Iwanami Y, Sugino K, et al. Using 6-min walk distance 
expressed as a percentage of reference to evaluate the effect of 
pulmonary rehabilitation in elderly patients with interstitial lung 
disease. J Cardiopulm Rehabil Prev. 2018; 38(5): 342–347, doi: 
10.1097/HCR.0000000000000305, indexed in Pubmed: 29485525.
